THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael O'Dwyer to Multiple Myeloma

Back to Details
This is a "connection" page, showing publications Michael O'Dwyer has written about Multiple Myeloma.
Michael O'Dwyer
Connection Strength
0.686
Multiple Myeloma
  1. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
    View in: PubMed
    Score: 0.239
  2. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021 01 25; 10(1):1859263.
    View in: PubMed
    Score: 0.180
  3. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 05 30; 380(22):2104-2115.
    View in: PubMed
    Score: 0.161
  4. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol Cancer Ther. 2013 Jun; 12(6):831-43.
    View in: PubMed
    Score: 0.106
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES